Amplifold closed a €5 million seed round to commercialize DNA origami‑based signal amplification for lateral flow assays (LFAs). The Munich spinout says its nanostructures can increase LFA analytical sensitivity up to 100‑fold while fitting existing manufacturing workflows, enabling rapid upgrades of point‑of‑care tests without retooling production. Investors included Matterwave Ventures and Xista Science Ventures; funds will support IVDR regulatory work and relocation to Martinsried’s biotechnology innovation center. Proof‑of‑concept work showed improved detection of cardiac troponin I in serum using the origami connectors to link detection antibodies to signal labels. Amplifold positions the tech as a plug‑in to upgrade existing rapid tests toward instrument‑level sensitivity at low cost, with near‑term commercial targets in cardiology and infectious disease diagnostics.